A randomized, double-blind, placebo-controlled trial of avatrombopag in patients with chemotherapy-induced thrombocytpenia

Trial Profile

A randomized, double-blind, placebo-controlled trial of avatrombopag in patients with chemotherapy-induced thrombocytpenia

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Avatrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors Dova Pharmaceuticals
  • Most Recent Events

    • 05 Jan 2018 New trial record
    • 03 Jan 2018 According to a Dova Pharmaceuticals media release, this trial is expected to begin in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top